C.R. Bard Faces Federal Trial Over Unapproved Antimicrobial Catheter
A federal trial over C.R. Bard's PowerPort catheter, lacking FDA clearance, begins April 21, 2026.
Why it matters: Legal and compliance teams in the medical device sector face heightened exposure to FDA enforcement and product liability trends. This trial will benchmark regulatory and litigation risks for in-house counsel.
- C.R. Bard's antimicrobial PowerPort catheter was marketed without FDA clearance.
- More than 3,231 lawsuits consolidated in MDL 3081 allege design-related injuries.
- The first trial in the Arizona MDL is set for April 21, 2026, in federal court.
- 438 adverse event reports were filed to the FDA between Dec. 2025 and Feb. 2026.
C.R. Bard is heading to trial in the U.S. District Court for the District of Arizona over its antimicrobial PowerPort catheter. Plaintiffs argue Bard's device was never FDA-cleared for its infection-prevention claims yet was widely sold to hospitals and clinicians.
The litigation—MDL 3081—brings together more than 3,231 lawsuits alleging the PowerPort's barium sulfate composition led to premature device fractures and serious infections. The case has drawn increased attention among in-house legal and compliance teams following hundreds of reported adverse events about device malfunction.
The first bellwether trial in the Arizona MDL is scheduled for April 21, 2026. (Bellwether trials are early test cases in mass litigation, used by both plaintiffs and defendants to gauge potential outcomes for related claims.) Outcomes will shape settlement and trial strategies industry-wide.
- According to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database, 438 complication reports for the PowerPort were submitted from December 2025 to February 2026. These numbers indicate significant safety concerns and increased regulatory scrutiny (see Device Lawsuit Overview).
The FDA has previously warned that “marketing a device without proper clearance raises significant compliance and patient safety risks.” Expert observers say outcomes in the Bard trial could influence how medical device companies structure risk analysis and regulatory compliance programs in the future.
By the numbers:
- 3,231 — Number of lawsuits consolidated in MDL 3081 as of April 2026
- 438 — FDA adverse event reports on PowerPort from Dec. 2025 to Feb. 2026
Yes, but: Bard maintains the PowerPort device met all regulatory and safety requirements at the time of marketing, a central dispute for the trial.
What's next: Opening arguments are slated for April 21, 2026, in the District of Arizona, with further bellwether trials likely to follow.